Undisclosed LRRK2 inhibitor therapeutic / AbbVie - LARVOL DELTA

A proteogenomic view of Parkinson's disease causality and heterogeneity. (PubMed, NPJ Parkinsons Dis) - "To date, this is the most comprehensive CSF-based proteomics profiling study in PD with 569 patients (350 idiopathic patients, 65 GBA + mutation carriers and 154 LRRK2 + mutation carriers), 534 controls, and 4135 proteins analyzed...Finally, we used proteomic data to stratify idiopathic patients into "endotypes". The identified endotypes show differences in cognitive and motor disease progression based on previously reported protein-based risk scores.Our findings not only contribute to the identification of new therapeutic targets but also to shape personalized medicine in CNS neurodegeneration."

Heterogeneity • Journal • CNS Disorders • Immunology • Inflammation • Metabolic Disorders • Movement Disorders • Parkinson's Disease • GPNMB

PROTEOMIC ANALYSIS OF THE PARKINSON DISEASE HETEROGENEITY: A STUDY ON PPMI PATIENT COHORTS (ADPD 2022) - "We examined three cohorts from the Parkinson Progression Marker Initiative (PPMI): manifest PD patients carrying LRRK2 or GBAmutations and idiopathic patients, each with their corresponding controls... Overall, our results showed molecular heterogeneity in the different cohorts. The proteomic biomarkers, the unique signature of the CSF as well as the causal targets we identified using both proteomics and genetics may influence how we define PD and the strategies to approach the identification of therapeutic targets."

Clinical • Heterogeneity • CNS Disorders • Movement Disorders • Parkinson's Disease • CD4 • CD8 • GBA